Smith & Nephew plc (SNN)
NYSE: SNN · Real-Time Price · USD
26.13
+0.41 (1.59%)
Feb 21, 2025, 4:00 PM EST - Market closed
Smith & Nephew Revenue
Smith & Nephew had revenue of $2.83B in the half year ending June 29, 2024, with 8.73% growth. This brings the company's revenue in the last twelve months to $5.64B, up 5.48% year-over-year. In the year 2023, Smith & Nephew had annual revenue of $5.55B with 6.40% growth.
Revenue (ttm)
$5.64B
Revenue Growth
+5.48%
P/S Ratio
2.02
Revenue / Employee
$295,687
Employees
19,081
Market Cap
11.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.55B | 334.00M | 6.40% |
| Dec 31, 2022 | 5.22B | 3.00M | 0.06% |
| Dec 31, 2021 | 5.21B | 652.00M | 14.30% |
| Dec 31, 2020 | 4.56B | -578.00M | -11.25% |
| Dec 31, 2019 | 5.14B | 234.00M | 4.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SNN News
- 5 days ago - Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand - GlobeNewsWire
- 18 days ago - Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes - GlobeNewsWire
- 24 days ago - Smith & Nephew Getting No Credit For Self-Improvement Efforts - Seeking Alpha
- 5 weeks ago - Smith+Nephew's ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable' Evidence Bar™ ratings from ECRI for pressure injury prevention - GlobeNewsWire
- 5 weeks ago - Topical Scar Treatment Market to Grow from $1.71 Billion in 2024 to $5.91 Billion by 2035 - Dominated by Smith & Nephew, Molnlycke Health Care, Alliance Pharma, HRA Pharma, and Rejuvaskin - GlobeNewsWire
- 2 months ago - Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty - GlobeNewsWire
- 2 months ago - Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty - GlobeNewsWire
- 3 months ago - Big investors call for break-up of Smith & Nephew, FT reports - Reuters